<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01144117</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT number: 2009-011516-37</org_study_id>
    <nct_id>NCT01144117</nct_id>
  </id_info>
  <brief_title>The Effects of Erythropoietin on Clinical Disability and Brain Pathology in Patients With Progressive Multiple Sclerosis</brief_title>
  <acronym>EPO-ProgMS</acronym>
  <official_title>Double Blind, Placebo-controlled Study to Assess the Effects of Erythropoietin on Clinical Disability and Brain Pathology as Shown by Magnetic Resonance Imaging in Patients With Progressive Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danish Research Centre for Magnetic Resonance</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In a double-blind, placebo-controlled, parallel group trial, recombinant human erythropoietin
      (rhEPO) (48000 IU) treatment or placebo will be administered weekly i.v. for 24 weeks: weekly
      for 12 weeks and bi-weekly for 12 weeks. Methylprednisolone (MP) 1 g i.v. will be
      administered before the first and second EPO/placebo administration. The 24-week treatment
      period will be followed by a 24-week observation period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with primary progressive MS or secondary progressive MS without relapses during the
      last 1 year will be suitable for the trial. In all 56 patients will be enrolled into the
      study.

      The primary outcome measure is the change from baseline to 24 weeks in a composite of maximum
      gait distance, 9-hole peg test, TRAIL making B comparing the placebo-treatment group with the
      EPO-treatment group.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2009</start_date>
  <completion_date type="Anticipated">April 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome measure is the change from baseline to 24 weeks in a composite of maximum gait distance, 9-hole peg test, TRAIL making B comparing the placebo-treatment group with the EPO-treatment group.</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparisons between the placebo-and the EPO-group regarding:difference in maximum gait distance between baseline and week 24.</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparisons between the placebo-and the EPO-group regarding:difference in 9-hole peg test</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparisons between the placebo-and the EPO-group regarding:difference in TRAIL making B</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Multiple Sclerosis (Primary or Secondary Progressive Phase).</condition>
  <arm_group>
    <arm_group_label>Erythropoietin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erythropoietin treated patients contra placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythropoietin</intervention_name>
    <description>Erythropoietin 48000 IU given I.V. in 17 courses</description>
    <arm_group_label>Erythropoietin</arm_group_label>
    <other_name>Epo, NeoRecormon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age between 19 and 60 years

          -  primary progressive MS or secondary progressive MS without relapses during the last
             one year

          -  duration of the disease of at least 2 years Clinical disability progression should
             have been observed in the 2 years prior to screening as per clinical judgment of the
             investigator. In addition, progression must be documented by an increase in the EDSS
             score of at least 0.5 points at any time during the 2 years prior to Screening; or
             progression of 1 point in the pyramidal, cerebellar, brain stem , visual or sensory
             functional system during the last 2 years. Should documented EDSS scores not be
             available, a written summary of the clinical evidence of disability progression in the
             previous 2 years must be submitted (for example walking distance or hand function).

          -  EDSS (Expanded Disability Status Scale) 4.0-6.5

          -  MRI fulfilling the Barkhof criteria for MS

          -  written informed consent

        Exclusion Criteria:

          -  pregnancy or period of breastfeeding or missing adequate contraceptive protection

          -  treatment with steroids in the last 30 days

          -  treatment with interferons, glatiramer acetate or IVIG in the last1 month prior to
             enrolment

          -  treatment with azathioprin, mitoxantrone or any other immuno-suppressive in the 6
             months prior to enrolment

          -  cardiac insufficiency (NYHA III/IV), cardiomyopathy, significant cardiac dysrhythmia
             requiring treatment, instable or advanced ischemic heart disease (CCS III or IV),
             malignant hypertension (systolic &gt; 180, diastolic &gt; 110)

          -  history of any haematological disorder

          -  history of renal insufficiency

          -  any medical psychiatric or other circumstances which impede or restrict the subjects
             participation in the study in the manner intended

          -  contraindication for contrast enhanced MRI (e.g. pace maker, aortic clip or any metal
             implant)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Schreiber, MD., Ph.d.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Per S Soerensen, MD., Prof</last_name>
    <role>Study Director</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen Schreiber, M.D., Ph.d.</last_name>
    <phone>+45 35 45 98 40</phone>
    <email>karen.schreiber@rh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Karen Schreiber</name>
      <address>
        <city>Copenhagen</city>
        <state>Oesterbro</state>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Schreiber, MD., Ph.d.</last_name>
      <phone>+45 35 45 98 40</phone>
      <email>karen.schreiber@rh.dk</email>
    </contact>
    <investigator>
      <last_name>Karen Schreiber, MD., Ph.d.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2010</study_first_submitted>
  <study_first_submitted_qc>June 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2010</study_first_posted>
  <last_update_submitted>August 4, 2011</last_update_submitted>
  <last_update_submitted_qc>August 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Professor Per Soelberg Sorensen, Rigshospitalet.</name_title>
    <organization>The Danish MS Research Center</organization>
  </responsible_party>
  <keyword>Progressive Multiple Sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

